Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Hepatology. 2020 Oct 1;72(5):1682–1700. doi: 10.1002/hep.31196

Figure 8. Effects of T0 and FDI-6 on expression of MATα1, FOXM1, p50 and p65, and tumor growth.

Figure 8.

A) MATα1, FOXM1, p50, and p65 levels after T0 treatment (5μM) in HepG2 cells. Results are expressed as mean % of DMSO control ± SEM from three experiments done in duplicates. *p<0.05 vs. DMSO. B) Representative pictures of liver xenograft tumors at day 28 after injection of HepG2 cells in DMSO (left) and T0 treatment (right) groups. Results are expressed as mean % of DMSO from n=8 per group. C) FOXM1 and MAT1A mRNA levels from T0 (25 mg/kg/d) or DMSO treated xenograft tumor tissues. Results are expressed as mean % of control ± SEM from eight mice/group. D) Representative H&E and IHC pictures are shown from n = 8 each. Original magnification for H&E and IHCs is X200. E) Protein expression of MATα1, FOXM1, p50, and p65 after FDI-6 treatment in HepG2 cells. Results are expressed as mean % of control ± SEM from three experiments done in triplicates. *p < 0.05 vs. DMSO. F) Representative pictures of liver syngeneic tumors at day 11 after injection of OKER cells in DMSO (left) and FDI-6 treatment (right, 25 mg/kg/d started on day 7) groups. Tumor volumes are summarized in the graph to the right. Results are expressed as mean of control ± SEM from eight mice/group. *p < 0.05 vs. DMSO. G) Representative H&E and IHC of syngeneic tumors treated with DMSO or FDI-6 from day 7 after injection and sacrificed at day 11. Original magnification for H&E is X100, and X200 for all IHC.